###begin article-title 0
###xml 111 116 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
Type I Interferons and Interferon Regulatory Factors Regulate TNF-Related Apoptosis-Inducing Ligand (TRAIL) in HIV-1-Infected Macrophages
###end article-title 0
###begin p 1
Conceived and designed the experiments: YH LZ YZ JCZ. Performed the experiments: YH AW MC LY. Analyzed the data: YH AW LZ YZ MC LY JCZ. Contributed reagents/materials/analysis tools: LZ YZ MC LY. Wrote the paper: YH AW JCZ.
###end p 1
###begin p 2
###xml 607 610 607 610 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ADA</sub>
###xml 617 622 617 622 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">JR-FL</sub>
###xml 632 635 632 635 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BAL</sub>
###xml 97 102 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 318 323 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 435 440 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 489 494 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 511 516 <span type="species:ncbi:9606">human</span>
###xml 602 605 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 612 615 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 627 630 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 711 716 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 742 747 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 1106 1111 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 1435 1440 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
TNF-related apoptosis-inducing ligand (TRAIL) is a member of the TNF family that participates in HIV-1 pathogenesis through the depletion of CD4+ T cells. TRAIL is expressed on the cell membrane of peripheral immune cells and can be cleaved into a soluble, secreted form. The regulation of TRAIL in macrophages during HIV-1 infection is not completely understood. In this study, we investigated the mechanism(s) of TRAIL expression in HIV-1-infected macrophages, an important cell type in HIV-1 pathogenesis. A human monocyte-derived macrophage (MDM) culture system was infected with macrophage-tropic HIV-1ADA, HIV-1JR-FL, or HIV-1BAL strains. TRAIL, predominantly the membrane-bound form, increased following HIV-1 infection. We found that HIV-1 infection also induced interferon regulatory factor (IRF)-1, IRF-7 gene expression and signal transducers and activators of transcription 1 (STAT1) activation. Small interfering RNA knockdown of IRF-1 or IRF-7, but not IRF-3, reduced STAT1 activation and TRAIL expression. Furthermore, the upregulation of IRF-1, IRF-7, TRAIL, and the activation of STAT1 by HIV-1 infection was reduced by the treatment of type I interferon (IFN)-neutralizing antibodies. In addition, inhibition of STAT1 by fludarabine abolished IRF-1, IRF-7, and TRAIL upregulation. We conclude that IRF-1, IRF-7, type I IFNs, and STAT1 form a signaling feedback loop that is critical in regulating TRAIL expression in HIV-1-infected macrophages.
###end p 2
###begin title 3
Introduction
###end title 3
###begin p 4
###xml 153 156 153 156 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005397-Wiley1">[1]</xref>
###xml 157 160 157 160 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005397-Janssen1">[3]</xref>
###xml 351 354 351 354 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005397-Ehrlich1">[4]</xref>
###xml 581 584 581 584 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005397-Herbeuval1">[5]</xref>
###xml 695 698 695 698 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005397-Kayagaki1">[6]</xref>
###xml 699 702 699 702 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005397-Herbeuval2">[9]</xref>
###xml 858 862 858 862 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005397-Ryan1">[10]</xref>
###xml 864 868 864 868 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005397-Huang1">[11]</xref>
###xml 976 980 976 980 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005397-Ryan1">[10]</xref>
###xml 981 985 981 985 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005397-Peng1">[13]</xref>
###xml 400 405 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 415 423 <span type="species:ncbi:9606">patients</span>
###xml 464 472 <span type="species:ncbi:9606">patients</span>
###xml 644 649 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 729 734 <span type="species:ncbi:9606">human</span>
###xml 779 784 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 1063 1068 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
TNF-related apoptosis-inducing ligand (TRAIL) is a member of the TNF superfamily and an important immune regulatory factor capable of inducing apoptosis [1]-[3]. TRAIL is expressed on the cell membrane of CD4+ T lymphocytes, natural killer cells, and mononuclear phagocytes (monocytes and macrophages) and can be cleaved into a soluble, secreted form [4]. The plasma levels of TRAIL are increased in HIV-1-infected patients compared to uninfected individuals, and patients receiving anti-retroviral therapy show decreased plasma TRAIL levels that correlate with reduced viral load [5]. Increased TRAIL expression is an important contributor to HIV-1-mediated apoptosis in bystander CD4+ T cells [6]-[9]. Furthermore, recombinant human TRAIL has been found to induce apoptosis in HIV-1-infected macrophages and cultured neurons as we have previously reported [10], [11]. Although the apoptotic signaling events of TRAIL have been studied extensively, including our recent work [10]-[13], the upstream molecular stimuli, particularly those that are responsible for HIV-1-mediated TRAIL upregulation, remain unclear.
###end p 4
###begin p 5
###xml 137 141 137 141 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005397-Gartner1">[14]</xref>
###xml 143 147 143 147 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005397-Gendelman1">[15]</xref>
###xml 355 359 355 359 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005397-Gabuzda1">[16]</xref>
###xml 360 364 360 364 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005397-Shieh1">[19]</xref>
###xml 452 456 441 445 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005397-Griffith1">[20]</xref>
###xml 513 517 491 495 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005397-Gong1">[21]</xref>
###xml 551 555 526 530 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005397-Herbeuval3">[22]</xref>
###xml 22 25 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 104 109 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 593 598 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
Macrophage (M)-tropic HIV strains preferentially infect mononuclear phagocytes, a cell type critical to HIV-1 replication in the disease [14], [15]. Infected mononuclear phagocytes disseminate virus to lymph nodes where CD4+ T lymphocytes become infected and to tissues, including the lung and central nervous system, where they serve as viral reservoirs [16]-[19]. TRAIL expression is induced by interferon (IFN)-alpha, -beta, and -gamma in monocytes [20], by IFN-alpha and -beta but not -gamma, in Jurkat cells [21], and by IFN-beta in CD4+ T cells [22]. However, limited information on how HIV-1 regulates TRAIL in mononuclear phagocytes has been reported to date.
###end p 5
###begin p 6
###xml 170 174 163 167 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005397-Gessani1">[23]</xref>
###xml 176 180 169 173 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005397-Siegal1">[24]</xref>
###xml 326 330 315 319 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005397-Oritani1">[25]</xref>
###xml 650 654 632 636 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005397-Darnell1">[26]</xref>
###xml 815 819 797 801 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005397-Levy1">[27]</xref>
###xml 838 842 820 824 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005397-Sato1">[28]</xref>
Type I IFNs IFN-alpha and -beta are primarily induced by plasmacytoid dendritic cells (pDCs) and in a lower amount by monocytes and macrophages following viral infection [23], [24]. All type I IFNs interact with the IFN-alpha receptor (IFNAR), which appears to couple to a uniform signal transduction cascade (for review, see [25]). IFN-alpha/beta binding triggers receptor dimerization and activation, leading to phosphorylation of a tyrosine residue on IFNAR. This phosphorylation stimulates the JAK/STAT pathway leading to the formation of signal transducers and activators of transcription 1 (STAT1) homodimers as well as heterodimers with STAT3 [26]. Activated STAT dimers translocate to the nucleus and bind to interferon stimulated response elements of the promoters for IFN-stimulated genes(for review, see [27]), including TRAIL [28].
###end p 6
###begin p 7
###xml 239 243 239 243 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005397-Veals1">[29]</xref>
###xml 337 341 337 341 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005397-Lohoff1">[30]</xref>
###xml 342 346 342 346 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005397-Honda1">[32]</xref>
###xml 494 498 494 498 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005397-Miyamoto1">[33]</xref>
###xml 499 503 499 503 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005397-Herbeuval4">[36]</xref>
###xml 675 679 675 679 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005397-Honda2">[37]</xref>
###xml 758 762 758 762 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005397-Clarke1">[38]</xref>
###xml 763 767 763 767 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005397-RomieuMourez1">[41]</xref>
###xml 488 493 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
IFN regulatory factors (IRFs) are a family of transcription factors that regulate the antiviral response. IRFs are closely related to type I IFNs and consist of nine mammalian proteins characterized by an amino-terminal DNA-binding domain [29]. Gene knockout of IRF-1, IRF-3, or IRF-7 results in high susceptibility to infectious agents [30]-[32]. IRF-1 and IRF-7 were identified by their ability to induce the transcription of type I IFN and IFN-inducible genes, and both are induced by HIV-1 [33]-[36]. IRF-1, IRF-3, and IRF-7 are constitutively expressed in most cell types, whereas the expression of IRF-1 and IRF-7 are more inducible following exposure of cells to IFNs [37]. In addition, IRF-1, IRF-3, and IRF-7 have been linked to TRAIL transcription [38]-[41]. However, the exact role of IRFs in the promotion of TRAIL expression, especially in mononuclear phagocytes, remains unclear.
###end p 7
###begin p 8
###xml 123 128 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 206 211 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 264 269 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 660 665 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 1005 1010 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 1060 1065 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 1165 1170 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
Using a monocyte-derived macrophage (MDM) model, we investigated how TRAIL expression is upregulated in macrophages during HIV-1 infection. Our results demonstrated that upregulation of TRAIL expression in HIV-1-infected MDM was predominantly membrane-associated. HIV-1 infection induced IRF-1 and IRF-7 gene expression and STAT1 phosphorylation in macrophages. Small interfering RNA (siRNA) knockdown of IRF-1 or IRF-7 but not IRF-3 reduced STAT1 activation and TRAIL expression. Treatment with various cytokines identified IFNs as the critical factors stimulating TRAIL expression. The upregulation of IRF-1, IRF-7, and TRAIL, and the activation of STAT1 by HIV-1 infection was reduced by the treatment of type I interferon neutralizing antibodies. In addition, inhibition of STAT1 by fludarabine abolished IRF-1, IRF-7, and TRAIL upregulation. These data suggest that IRF-1, IRF-7, Type I IFNs, and STAT1 form a signaling feedback loop and cooperatively regulate TRAIL expression in macrophages during HIV-1 infection. Understanding the signaling events in HIV-1-infected macrophages may lead to the development of new therapies to alleviate macrophage-mediated HIV-1 pathogenesis by reducing the expression of death ligand TRAIL.
###end p 8
###begin title 9
Materials and Methods
###end title 9
###begin title 10
Reagents
###end title 10
###begin p 11
###xml 155 160 <span type="species:ncbi:10090">Mouse</span>
###xml 313 318 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
Recombinant proteins, neutralizing antibodies, and chemicals were obtained as follows: IL-1beta, TNF-alpha, IFN-gamma, IFN-beta neutralizing antibody, and Mouse IgG1 (R&D Systems, Minneapolis, MN); IFN-alpha, IFN-beta, and IFN-alpha neutralizing antibody (PBL Interferon Source, Piscataway, NJ); Aidovudine (AZT, HIV-1 reverse transcriptase inhibitor), fludarabine, and lipopolysaccharide (LPS) (Sigma-Aldrich, St. Louis, MO).
###end p 11
###begin title 12
###xml 26 31 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
Monocyte cell culture and HIV-1 infection
###end title 12
###begin p 13
###xml 184 188 184 188 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005397-Gendelman2">[42]</xref>
###xml 259 260 259 260 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">6</sup>
###xml 0 5 <span type="species:ncbi:9606">Human</span>
###xml 73 78 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 419 424 <span type="species:ncbi:9606">human</span>
###xml 598 603 <span type="species:ncbi:9606">human</span>
Human monocytes were isolated from peripheral blood mononuclear cells of HIV-1, -2, and hepatitis B seronegative donors after leukopheresis and counter current centrifugal elutriation [42]. Monocytes were cultured as adherent monolayers at a density of 1.1x106 cells/well in 24-well plates and cultivated in Dulbecco's modified Eagles medium (DMEM, GIBCO Invitrogen Corp, Carlsbad, CA) with 10% heat-inactivated pooled human serum (Cambrex Bio Science, Walkersville, MD), 50 microg/ml gentamicin, 10 microg/ml ciprofloxacin (Sigma-Aldrich, St. Louis, IL), and 1000 U/ml highly purified recombinant human macrophage colony stimulating factor (M-CSF) (a generous gift from the Wyeth Institute, Cambridge, MA).
###end p 13
###begin p 14
###xml 329 333 321 325 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005397-Gendelman2">[42]</xref>
###xml 49 54 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 259 264 <span type="species:ncbi:9606">human</span>
Seven days after plating, MDM were infected with HIV-1 strains ADA, BAL, or JR-FL at a multiplicity of infection (MOI) of 0.1. On the second day after infection, media were removed and substituted with MDM culture media (DMEM with 10% heat-inactivated pooled human serum, 50 microg/ml gentamicin, and 10 microg/ml ciprofloxacin) [42]. Stock virus was screened for mycoplasma and endotoxin using hybridization and Limulus amebocyte lysate assays, respectively. Five days after infection, cells were changed to 0.5 ml/well fresh medium for 24 hours. Culture supernatants were obtained and subsequently stored at -80degreesC until assayed. Filtration of supernatants was performed with Amicon Ultra 100 K nominal molecular weight limit devices (Millipore, Billerica, MA).
###end p 14
###begin title 15
###xml 16 21 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
Measurements of HIV-1 reverse transcriptase (RTase) activity
###end title 15
###begin p 16
###xml 262 263 250 251 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 270 271 258 259 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">3</sup>
###xml 555 559 537 541 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005397-Koenig1">[18]</xref>
###xml 0 5 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
HIV-1 RTase activity was determined in triplicate samples of cell culture fluids. Supernatant (10 microl) was incubated in a reaction mixture of 0.05% Nonidet P-40, 10 microg of poly(A)/ml, 0.25 microg of oligo(dT)/ml, 5 mM dithiothreitol, 150 mM KCl, 15 mM MgCl2, and [3H]TTP in Tris-HCl buffer (pH 7.9) for 24 h at 37degreesC. Radiolabeled nucleotides were precipitated with cold 10% trichloroacetic acid on filter paper plates in an automatic cell harvester and washed with 95% ethanol. Radioactivity was estimated by liquid scintillation spectroscopy [18].
###end p 16
###begin title 17
RNA extraction and TaqMan real-time RT-PCR
###end title 17
###begin p 18
###xml 134 139 <span type="species:ncbi:9606">human</span>
###xml 256 261 <span type="species:ncbi:9606">human</span>
Total RNA was isolated with TRIzol Reagent (Invitrogen) and RNeasy Mini Kit (QIAGEN Inc., Valencia, CA). Assays-on-Demand primers for human TRAIL (ID#, Hs00234356_m1), IRF-1 (ID#, Hs00971965_m1), IRF-3 (ID#, Hs00155574_m1), IRF-7 (ID#, Hs00185375_m1), and human GAPDH (ID#, 4310884E) were purchased from Applied Biosystems, Inc. (Foster City, CA). Real-time reverse-transcription polymerase chain reaction (RT-PCR) was carried out using the one-step quantitative TaqMan Real-time RT-PCR system (Applied Biosystems). TRAIL, IRF-1, IRF-3, and IRF-7 mRNA levels were determined and standardized with a GAPDH internal control, and normalized to uninfected cells using comparative DeltaDeltaCT method. All primers used in the study were tested for amplification efficiencies and the results were similar.
###end p 18
###begin title 19
TRAIL and CCL5 ELISA
###end title 19
###begin p 20
###xml 117 121 117 121 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005397-Ryan1">[10]</xref>
###xml 123 127 123 127 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005397-Cotter1">[43]</xref>
Supernatants from MDM were collected for TRAIL and CCL5 determination by ELISA (R&D Systems) as described previously [10], [43]. The sensitivity of soluble TRAIL and RANTES ELISA is 10 pg/ml. To assess concentrations of TRAIL in cell lysates of macrophages, we replaced the cell lysis buffer in the ELISA system with a lysis buffer from Pierce (Rockford, IL), which provides better lysis effect for membrane protein; the sensitivity for this assay was 100 pg/ml for TRAIL.
###end p 20
###begin title 21
Western blot analysis
###end title 21
###begin p 22
###xml 674 685 <span type="species:ncbi:3704">horseradish</span>
###xml 719 725 <span type="species:ncbi:9986">rabbit</span>
###xml 762 767 <span type="species:ncbi:10090">mouse</span>
Cell lysates from macrophages were prepared with M-PER Mammalian Protein Extraction Buffer (Pierce). Protein concentration was determined using the BCA Protein Assay Kit (Pierce). Protein (30 microg) was electrophoresed on pre-cast 8% SDS-PAGE and transferred to an Immuno-Blot PVDF membrane (Bio-Rad, Hercules, CA). Antibodies specific for Phospho-STAT1 at tyrosine 701, total STAT1, IRF-3, and retinoic acid-inducible gene I (RIG-I) were from Cell Signaling Technology, Inc. (Danvers, MA). Loading control beta-actin proteins were detected using anti-beta-actin (Sigma-Aldrich) antibodies. Membranes were treated overnight with primary antibody at 4degreesC followed by a horseradish peroxidase-ligand secondary anti-rabbit (Cell Signaling Technology) or anti-mouse (Cell Signaling Technology) antibody for 1 hour at room temperature. Antigen-antibody complexes were visualized by enhanced chemiluminescence (Amersham Biosciences, Piscataway, NJ) and captured with CL-X Posuretrade mark Film (Pierce). For data quantification the films were scanned with a CanonScan 9950F scanner; the acquired images were then analyzed on a Macintosh computer using the public domain NIH image program ().
###end p 22
###begin title 23
siRNA transfection
###end title 23
###begin p 24
###xml 536 541 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
Pre-designed siRNA duplexes for IRF-1 (ID#, 115266), IRF-3 (ID#, 115222), or IRF-7 (ID#, 115481) were synthesized by Ambion Inc. (Austin, Texas). Two days post-infection MDM were transfected with 120 nM siRNA duplex for 48-96 hours in the presence of siIMPORTER (Upstate Cell Signaling Solutions, Charlottesville, VA) according to the manufacturer's instructions. A validated Silencer Negative Control #1 siRNA (Ambion Inc.) was also transfected at the same concentration as IRFs siRNA. To evaluate transfection efficiency, control and HIV-1-infected MDM were transfected with Silencer FAM-labeled Negative Control #1 siRNA (green fluorescence tagged siRNA) (Ambion Inc.). At 48 hours post-transfection, cells were incubated with Hoechst 33342 (Sigma) for nuclear staining, transfected and total cells were counted.
###end p 24
###begin title 25
Immunocytochemical assays
###end title 25
###begin p 26
###xml 0 5 <span type="species:ncbi:9606">Human</span>
###xml 308 313 <span type="species:ncbi:9606">human</span>
###xml 428 433 <span type="species:ncbi:10090">mouse</span>
###xml 439 444 <span type="species:ncbi:9606">human</span>
###xml 514 519 <span type="species:ncbi:10090">mouse</span>
###xml 523 529 <span type="species:ncbi:9986">rabbit</span>
###xml 656 661 <span type="species:ncbi:10090">mouse</span>
###xml 751 757 <span type="species:ncbi:9986">rabbit</span>
Human MDM were plated on 15 mm cover slips in 24-well plates. Five days after infection, cells were fixed with 4% paraformaldehyde at room temperature then incubated with methanol for 20 minutes at -20degreesC. Fixed cells were blocked with 3% BSA in PBS and then incubated with primary antibodies to TRAIL (human TRAIL specific polyclonal, Santa Cruz Biotechnology, Inc., Santa Cruz, CA) mixed with antibody to p24 (monoclonal mouse anti-human p24, IgG, DAKO Corp, Carpinteria, CA) at 4degreesC overnight. Normal mouse or rabbit IgG with matched isotype were used as negative controls for the staining. Cultures were washed and secondary antibodies, anti-mouse IgG (coupled with green dye, Alexa Flour 488, Molecular Probes, Eugene, Oregon), or anti-rabbit IgG (coupled with a info-red dye, Alexa Fluor 647, Molecular Probes) were added for 1 hour at room temperature. Nuclei DNA were labeled with Hoechst 33342 (Sigma-Aldrich) for 10 minutes at room temperature. Cover slips were mounted on glass slides with mounting medium (Sigma-Aldrich). Triple immunostaining was examined by a Bio-Rad MRC1024ES lASER scanning confocal microscope using a triple laser line and simultaneous triple display mode of the Bio-Rad LaserSharp imaging program.
###end p 26
###begin title 27
Statistical tests
###end title 27
###begin p 28
Data were analyzed as means+/-standard deviation (SD) unless otherwise specified. The data were evaluated statistically by the analysis of variance (ANOVA), followed by the Tukey-test for paired observations. Significance was considered with a p value less than 0.05. All experiments were performed with at least three donors to account for any donor specific differences. Assays were performed at least three times in triplicate or quadruplicate.
###end p 28
###begin title 29
Results
###end title 29
###begin title 30
###xml 0 5 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 112 117 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
HIV-1-induced upregulation of TRAIL expression is predominantly membrane-associated and dependent on productive HIV-1 infection
###end title 30
###begin p 31
###xml 92 95 92 95 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005397-Zhang1">[7]</xref>
###xml 97 101 97 101 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005397-Ryan1">[10]</xref>
###xml 220 223 220 223 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ADA</sub>
###xml 230 235 230 235 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">JR-FL</sub>
###xml 246 249 246 249 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BAL</sub>
###xml 417 420 417 420 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ADA</sub>
###xml 430 433 430 433 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BAL</sub>
###xml 486 491 486 491 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">JR-FL</sub>
###xml 493 500 493 500 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0005397-g001">Fig. 1A</xref>
###xml 619 626 619 626 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0005397-g001">Fig. 1A</xref>
###xml 840 847 840 847 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0005397-g001">Fig. 1B</xref>
###xml 855 858 855 858 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ADA</sub>
###xml 36 41 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 201 206 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 215 218 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 225 228 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 241 244 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 260 265 <span type="species:ncbi:9606">human</span>
###xml 338 343 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 384 389 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 412 415 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 425 428 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 481 484 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 510 515 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 568 573 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 850 853 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 905 910 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
Upregulation of TRAIL expression by HIV-1-infected macrophages has been previously reported [7], [10]; our current study investigated the mechanisms behind this upregulation. We used macrophage-tropic HIV-1 strains HIV-1ADA, HIV-1JR-FL, and HIV-1BAL to infect human MDM. Five days after infection, culture supernatants were collected and HIV-1 viral infectivity was determined by the HIV-1 RTase activity assay. HIV-1ADA and HIV-1BAL demonstrated higher infectivity as compared to HIV-1JR-FL (Fig. 1A). AZT, a HIV-1 reverse transcriptase inhibitor, completely blocked HIV-1 reverse transcription of all strains tested (Fig. 1A). The investigated macrophage-tropic viral strains all strongly upregulated TRAIL expression levels as indicated by real-time RT-PCR, and this upregulation was then blocked by reverse transcriptase inhibitor AZT (Fig. 1B). HIV-1ADA strain was used thereafter and referred to as HIV-1.
###end p 31
###begin title 32
###xml 20 25 <span type="species:ncbi:9606">human</span>
###xml 67 72 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
TRAIL expression in human macrophages increases when infected with HIV-1.
###end title 32
###begin p 33
###xml 39 42 39 42 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ADA</sub>
###xml 49 54 49 54 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">JR-FL</sub>
###xml 64 67 64 67 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BAL</sub>
###xml 527 530 527 530 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ADA</sub>
###xml 5 10 <span type="species:ncbi:9606">Human</span>
###xml 34 37 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 44 47 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 59 62 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 217 222 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 475 480 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 493 498 <span type="species:ncbi:9606">Human</span>
###xml 522 525 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 857 862 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
A-B. Human MDM were infected with HIV-1ADA, HIV-1JR-FL, or HIV-1BAL in the presence or absence of AZT. Cells (total RNA) and culture supernatants were collected 5 days after infection. A. Supernatants were tested for HIV-1 RTase activity. B. TRAIL expression was determined by real-time RT-PCR. Results were normalized to GAPDH expression and shown as fold change over control. ** indicates p<0.01 when compared to control; ## indicates p<0.01 when compared to corresponding HIV-1 group. C-F. Human MDM were infected with HIV-1ADA. Samples were collected 1, 3, 5, and 7 days after infection. C. Supernatants were tested for RTase activity. D. TRAIL expression was determined by real-time RT-PCR. E-F. TRAIL protein levels in cell lysate (E) and culture supernatants (F) were measured by TRAIL ELISA. Open bars represent control MDM and solid bars represent HIV-1-infected MDM. ** indicates p<0.01, * indicates p<0.05 when compared to the corresponding control. Data are representative of three donors.
###end p 33
###begin p 34
###xml 262 269 262 269 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0005397-g001">Fig. 1C</xref>
###xml 437 444 437 444 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0005397-g001">Fig. 1D</xref>
###xml 811 818 811 818 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0005397-g001">Fig. 1E</xref>
###xml 1194 1201 1194 1201 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0005397-g001">Fig. 1F</xref>
###xml 28 33 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 218 223 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 514 517 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 668 673 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 1084 1089 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
To determine the effects of HIV-1 infection on TRAIL mRNA and protein levels in MDM, we used real-time RT-PCR and an ELISA-based detection system, respectively. As the infection progressed from day 1 through day 7 the HIV-1 RTase activity continued to increase (Fig. 1C). TRAIL mRNA expression was not significantly changed at 1 day post-infection but was significantly upregulated on days 3, 5, and 7 as compared to uninfected control (Fig. 1D). TRAIL mRNA upregulation peaked at day 5 and was 7.3-fold higher in HIV-infected MDM as compared to uninfected control. To determine the protein levels of TRAIL, whole-cell lysates were collected 1, 3, 5, and 7 days after HIV-1 infection and then subjected to ELISA detection. TRAIL protein levels increased starting at 3 days and peaked at 5 days after infection (Fig. 1E). After 7 days of infection, cultures underwent significant macrophage cell death (approximately 50% loss in cell viability, data not shown) and the protein level of TRAIL decreased accordingly. TRAIL ELISA was also used to measure soluble TRAIL protein within the HIV-1-infected and uninfected MDM supernatants and no significant changes in TRAIL concentrations were found (Fig. 1F). These results indicate TRAIL upregulation is associated with membrane-bound TRAIL rather than the soluble form.
###end p 34
###begin p 35
###xml 319 329 319 329 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0005397-g002">Fig. 2A, D</xref>
###xml 353 363 353 363 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0005397-g002">Fig. 2B, D</xref>
###xml 439 449 439 449 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0005397-g002">Fig. 2E, H</xref>
###xml 586 599 586 599 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0005397-g002">Fig. 2E, F, H</xref>
###xml 84 89 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 184 189 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 366 371 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
We further specified that the membrane-bound form of TRAIL is upregulated following HIV-1 infection by using immunocytochemistry and confocal microscopy. During the progression of MDM HIV-1 infection, the percentage of infected cells continued to increase. At days 5, staining of uninfected MDM was positive for TRAIL (Fig. 2A, D) and negative for p24 (Fig. 2B, D). HIV-1-infected MDM culture showed a dramatic increase in TRAIL staining (Fig. 2E, H), particularly those MDM that were adjacent to p24-positive multinucleated giant cells expressed high levels of TRAIL surface staining (Fig. 2E, F, H). Thus, it is likely that uninfected macrophages increase TRAIL protein synthesis in response to diffusible factor(s) released by infected cells.
###end p 35
###begin title 36
###xml 34 39 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
Membrane-bound TRAIL increases in HIV-1-infected macrophage culture.
###end title 36
###begin p 37
###xml 0 5 <span type="species:ncbi:9606">Human</span>
###xml 29 34 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 87 92 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 216 221 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
Human MDM were infected with HIV-1 for 5 days and then stained with antibodies to p24 (HIV-1 infection marker, green) and TRAIL (red). Nuclei (blue) were labeled with Hoechst 33342. A-D. Control uninfected MDM. E-H. HIV-1-infected MDM. Panels D and H are merged pictures of A-C and E-G, respectively. Images were acquired from a Bio-Rad MRC1024ES LASER scanning confocal microscope. Magnifications: A-H. 600x. Panels are representative of 4 separate donors.
###end p 37
###begin title 38
###xml 0 5 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
HIV-1 infection induces IRF-1, IRF-7 gene expression and STAT1 phosphorylation in macrophages
###end title 38
###begin p 39
###xml 401 411 401 411 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0005397-g003">Fig. 3A, C</xref>
###xml 572 579 572 579 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0005397-g003">Fig. 3B</xref>
###xml 739 748 735 744 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0005397-g003">Fig. 3A&#8211;C</xref>
###xml 153 158 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 243 248 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 323 328 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
To determine the molecular mechanisms that mediate TRAIL expression, we studied the signaling pathways in the macrophage innate immunity that respond to HIV-1 infection. First, we examined the regulation of the IRF transcription factors after HIV-1 infection of MDM. The expression levels of IRF-1 and IRF-7 increased upon HIV-1 infection and the increase occurred as early as 3 days after infection (Fig. 3A, C). In contrast, the expression levels of IRF-3 remained the same except at 5 days after infection, where an average 26% reduction in IRF-3 expression was found (Fig. 3B). We also treated MDM with IFN-alpha and observed an increase in IRF-1, IRF-3, and IRF-7 gene expression, confirming all these genes are IFN-stimulated genes (Fig. 3A-C).
###end p 39
###begin title 40
###xml 0 5 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
HIV-1 infection induces IRF-1 and IRF-7 gene expression and STAT1 phosphorylation at Tyr701 in macrophages.
###end title 40
###begin p 41
###xml 23 28 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 241 246 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
MDM were infected with HIV-1 and cell lysates and RNA were collected 1, 3, 5, and 7 days after infection. A-C. Real-time RT-PCR was used to detect IRF-1 (A), IRF-3 (B), and IRF-7 (C). Open bars represent control MDM and solid bars represent HIV-1-infected MDM. IFN-alpha (1000 Units/ml) was also used to stimulate MDM for 24 hours, the effect on IRFs expression is shown in each panel as the diagonal striped bar. D. Phospho-STAT1 (p-STAT1, Tyr701) and total STAT1 were detected by Western blotting. beta-actin was used as a loading control. E. Levels of p-STAT1 were normalized as a ratio of p-STAT1 to STAT1 after densimetrical quantification of panel D and shown as fold change relative to control (1 dpi). F. Levels of STAT1 were normalized as a ratio of STAT1 to beta-actin and shown as fold change relative to control (1 dpi). Results are shown as the average+/-SEM in experiments performed with three different donors. *, p<0.05 compared with day-matched control. **, p<0.01 compared to day-matched control.
###end p 41
###begin p 42
###xml 340 350 340 350 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0005397-g003">Fig. 3D, E</xref>
###xml 429 439 429 439 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0005397-g003">Fig. 3D, F</xref>
###xml 223 228 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 353 358 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 480 485 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
IRF-1 and IRF-7 are able to induce the production of type I IFNs, which primarily activate STAT1/STAT2 signaling molecules. We next determined the phosphorylation at Tyr701 of STAT1 that is obligatory for STAT1 activation. HIV-1 induced STAT1 phosphorylation 3 days after infection, and the phosphorylation persisted for 4 additional days (Fig. 3D, E). HIV-1 infection also increased total STAT1 at 5 and 7 days after infection (Fig. 3D, F). Together, these data demonstrate that HIV-1 infection induces activation of STAT1 through phosphorylation of Tyr701 as well as an increase in total STAT1 protein levels in MDM. The similar kinetics of IRF-1, IRF-7 expression, STAT1 activation, and TRAIL production indicates these molecules may associate with the same signaling pathway.
###end p 42
###begin title 43
###xml 63 68 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
siRNA knockdown of IRF-1 and IRF-7 reduces TRAIL expression in HIV-1-infected macrophages
###end title 43
###begin p 44
###xml 318 325 318 325 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0005397-g004">Fig. 4A</xref>
###xml 679 688 667 676 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0005397-g004">Fig. 4B&#8211;D</xref>
###xml 865 872 853 860 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0005397-g004">Fig. 4E</xref>
###xml 1069 1076 1057 1064 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0005397-g004">Fig. 4F</xref>
###xml 1351 1358 1339 1346 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0005397-g004">Fig. 4G</xref>
###xml 252 257 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 477 482 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 563 568 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 647 650 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 773 776 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 1136 1141 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 1209 1214 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 1271 1276 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 1489 1494 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
To further elucidate whether increased levels of IRFs mediate the increase in TRAIL transcription, we transfected IRF-1, IRF-3 or IRF-7 siRNA, and a nonspecific siRNA as a control in MDM cultures. siRNA was successfully delivered into both control and HIV-1-infected MDM, as demonstrated by FAM-labeled control siRNA (Fig. 4A). The transfection efficiency, measured by counting FAM-positive cells within 200 total cells, was approximately approximately70% for both control and HIV-1-infected MDM. The levels of IRF-1, IRF-3, and IRF-7 following siRNA delivery in HIV-1-infected macrophages were 33%, 14%, and 28% of non-specific siRNA-transfected HIV-infected MDM, respectively (Fig. 4B-D). STAT1 phosphorylation was significantly reduced after IRF-1 or IRF-7 knockdown in HIV-infected MDM, but was unchanged after IRF-3 knockdown when compared with control siRNA (Fig. 4E). Similarly, TRAIL expression levels remained unchanged after IRF-3 siRNA transfection, but were significantly reduced after IRF-1 siRNA transfection and were blocked by IRF-7 siRNA transfection (Fig. 4F). The viral replication in each group was monitored by the HIV-1 RTase activity assay. Knocking down IRF-1 with siRNA decreased the HIV-1 infection levels, whereas the IRF-7 knockdown increased HIV-1 infection levels. Infection levels in IRF-3 knockdown remained unchanged (Fig. 4G). These data demonstrate that IRF-1 and IRF-7 are critical to the activation of STAT1 and the upregulation of TRAIL expression in HIV-1-infected macrophages.
###end p 44
###begin title 45
###xml 89 94 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
siRNA knockdown of IRF-1 and IRF-7 reduces STAT1 phosphorylation and TRAIL expression in HIV-1-infected macrophages.
###end title 45
###begin p 46
###xml 15 20 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 790 795 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 894 897 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 961 964 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
Two days after HIV-1 infection, MDM were transfected with siRNA for IRF-1, -3, or -7. A. Forty-eight hours later, successful transfections were confirmed by Silencer FAM-labeled Negative Control #1 siRNA transfection indicator (green). Hoechst 33258 (nucleus marker, blue) was used to visualize the total cell number. B-D. Total RNA was collected 48 hours post-transfection and mRNA levels of IRF-1(B), -3(C), or -7(D) were determined by real-time RT-PCR. E. Ninety-six hours after transfection, p-STAT1 and total STAT1 were detected by Western blotting. beta-actin was used as a loading control. F. TRAIL expression levels were determined by real-time RT-PCR. Results were normalized with GAPDH and shown as the fold change over non-specific siRNA control. G. Supernatants were tested for HIV-1 RTase activity. ** indicates p<0.01 when compared to control; # indicates p<0.05 when compared to HIV group with siRNA control; ## indicates p<0.01 when compared to HIV group with siRNA control. Data are representative of three donors.
###end p 46
###begin p 47
###xml 199 203 199 203 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005397-Sato2">[31]</xref>
###xml 358 366 358 366 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="pone.0005397.s001">Fig. S1A</xref>
###xml 526 530 526 530 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005397-Lin1">[44]</xref>
###xml 628 636 628 636 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="pone.0005397.s001">Fig. S1B</xref>
###xml 338 343 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 609 614 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 710 715 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
One unexpected finding in these IRF siRNA knockdown experiments was that IRF-3 was not required for IFN induction. It is well established that IRF3 is involved in IFN and IFN target genes inductions [31]. We further analyzed the protein knockdown of IRF-3 and found that the IRF-3 siRNA transfection reduced IRF-3 protein level by 60% in HIV-1-infected MDM (Fig. S1A). To further demonstrate the function of IRF-3 has been impaired after IRF-3 knockdown, we tested CCL5, a chemokine whose transcription is controlled by IRF-3 [44], and found that CCL5 was significantly downregulated after IRF-3 knockdown in HIV-1-infected MDM(Fig. S1B). These data suggest that knocking down IRF-3 is not sufficient to block HIV-1-induced STAT1 activation and TRAIL expression.
###end p 47
###begin title 48
IFNs potently increase macrophage TRAIL levels
###end title 48
###begin p 49
###xml 103 107 96 100 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005397-Esser1">[45]</xref>
###xml 109 113 102 106 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005397-Zhao1">[46]</xref>
###xml 253 257 242 246 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005397-Ryan1">[10]</xref>
###xml 620 624 602 606 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005397-Halaas1">[47]</xref>
###xml 679 686 661 668 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0005397-g005">Fig. 5A</xref>
###xml 793 803 775 785 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0005397-g005">Fig. 5B, C</xref>
###xml 1122 1131 1086 1095 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0005397-g005">Fig. 5A&#8211;C</xref>
###xml 87 92 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
Macrophages release various inflammatory cytokines such as IL-1beta and TNF-alpha upon HIV-1 infection [45], [46]. We previously reported LPS- and IFN-gamma-treated macrophages have higher levels of cell-surface TRAIL through analysis by flow cytometry [10]. In this study, we used quantitative TRAIL ELISA and evaluated whether TRAIL synthesis by macrophages is mediated by inflammatory cytokines, such as IL-1beta and TNF-alpha. We treated MDM with a panel of inflammatory cytokines and LPS. LPS has been reported to increase both forms of TRAIL in MDM, and it served as positive control in our TRAIL detection system [47]. TRAIL mRNA increased in response to LPS stimulation (Fig. 5A), and TRAIL protein increased modestly in the cell lysates and supernatants in response to LPS treatment (Fig. 5B, C). Treatment of MDM with individual cytokines IL-1beta (50 ng/ml) or TNF-alpha (100 ng/ml) did not change membrane-bound or soluble TRAIL protein levels nor were TRAIL mRNA levels affected. In contrast, IFNs, including IFN-alpha, IFN-beta, and IFN-gamma, caused a significant increase in TRAIL protein and mRNA levels (Fig. 5A-C). Macrophages do not typically produce type II IFNs, thus type I IFNs remained the focus of our investigation.
###end p 49
###begin title 50
IFNs are potent stimulators of TRAIL expression in macrophages.
###end title 50
###begin p 51
###xml 0 5 <span type="species:ncbi:9606">Human</span>
###xml 29 34 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 304 309 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
Human MDM were infected with HIV-1 or stimulated with different inflammatory cytokines IL-1beta (50 ng/ml), TNF-alpha (100 ng/ml), IFN-alpha (1000 Units/ml), IFN-beta (1000 Units/ml), IFN-gamma (100 ng/ml), or LPS (100 ng/ml). Cell lysates and culture supernatants were either collected 5 days following HIV-1 infection or 24 hours following stimulation. A. TRAIL expression was determined by real-time RT-PCR. B-C, TRAIL protein levels in cell lysate and culture supernatants were measured by ELISA. * indicates p<0.05, ** indicates p<0.01 when compared to control. Data are representative of three donors.
###end p 51
###begin title 52
###xml 30 35 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
Increased TRAIL expression in HIV-1-infected macrophages is dependent on type I IFN activity
###end title 52
###begin p 53
###xml 71 75 71 75 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005397-Durbin1">[48]</xref>
###xml 77 81 77 81 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005397-Meraz1">[49]</xref>
###xml 713 720 699 706 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0005397-g006">Fig. 6A</xref>
###xml 871 878 850 857 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0005397-g006">Fig. 6B</xref>
###xml 1161 1168 1140 1147 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0005397-g006">Fig. 6C</xref>
###xml 1300 1310 1279 1289 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0005397-g006">Fig. 6D, E</xref>
###xml 1433 1443 1412 1422 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0005397-g006">Fig. 6F, G</xref>
###xml 110 115 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 342 347 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 933 938 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 973 978 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 1105 1110 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 1391 1396 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 1544 1549 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
STAT1 activation is essential for the cells to response to type I IFNs [48], [49]. STAT1 activation in MDM by HIV-1-infection suggests there are type I IFNs in the culture supernatant acting in autocrine and paracrine manner. To test whether type I IFNs were responsible for STAT1 activation and the subsequent increase in TRAIL levels after HIV-1-infection of MDM, type I IFN-neutralizing antibodies were administered. The type I IFN-neutralizing antibodies worked effectively because inhibition of IFN-alpha-induced STAT1 phosphorylation was found to be 92% for IFN-alpha-neutralizing antibodies, and inhibition of IFN-beta-induced STAT1 phosphorylation (54%) were observed by IFN-beta-neutralizing antibodies (Fig. 6A). In addition, TRAIL expression was reduced by 97% and 79% after the treatment with the IFN-alpha- or IFN-beta-neutralizing antibodies, respectively (Fig. 6B). We then added type I IFN-neutralizing antibodies to HIV-1-infected MDM every 24 hours after HIV-1 infection until the fifth day. The neutralizing antibodies did not appear to change the RTase activity, but partially blocked HIV-1-stimulated STAT1 phosphorylation (54% inhibition, Fig. 6C). Moreover, membrane-bound TRAIL and TRAIL levels were reduced by the neutralizing antibodies as compared to IgG control antibody (Fig. 6D, E). The addition of neutralizing antibodies against type I IFNs partially blocked HIV-1-induced IRF-1 and IRF-7 expression (Fig. 6F, G). These data further support the hypothesis that increased IRF-1, IRF-7, and TRAIL expression after HIV-1 infection is reliant on type I IFNs.
###end p 53
###begin title 54
###xml 23 28 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
Type I interferon from HIV-1-infected macrophages induces STAT1 phosphorylation, IRF-1, IRF-7, and TRAIL expression.
###end title 54
###begin p 55
###xml 558 563 <span type="species:ncbi:9606">Human</span>
###xml 587 592 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 1204 1209 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 1450 1455 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 1853 1858 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
A. MDM were treated with IFN-alpha (1000 Units/ml) or IFN-beta (1000 Units/ml) with or without their corresponding neutralizing antibodies. Cell lysates were collected 2 hours later and subjected to Western blotting for p-STAT1 and STAT1. beta-actin was used as a loading control. B. 24 hours after the treatment, TRAIL expression was determined by real-time RT-PCR. ** denotes p<0.01 compared with IgG control; ## indicates p<0.01 compared with the corresponding IFN group. Experiments are representative of duplicate assays from two different donors. C-G. Human MDM were infected with HIV-1 for 5 days with or without type I IFNs-neutralizing antibodies and total RNA and cell lysates were collected. C. Cell lysates were subjected to Western blotting for p-STAT1 and STAT1. D. TRAIL expression was determined by real-time RT-PCR. E. TRAIL protein levels in cell lysates were detected by ELISA. Experiments are representative of three different donors. *, p<0.05 compared with neutralizing antibodies treatment. F-G. IRF-1(F) and IRF-7(G) expression were determined by real-time RT-PCR. Results were shown as the average+/-SEM in experiments performed with three different donors. H. Supernatants from HIV-1 culture were collected 5 days after infection and filtered with 100 k centrifugal filter device. The flow-through was transferred to control MDM for 2 hours and STAT1 phosphorylation was determined by Western blotting. I. Supernatants from HIV-1 culture were transferred to control MDM culture with or without IFN-alpha- or IFN-beta- neutralizing antibodies. Cell lysates were collected 2 hours later and subjected to Western blotting for p-STAT1 and STAT1. J. Twenty-four hours after the treatment, TRAIL expression was determined by real-time RT-PCR. ** indicates p<0.01 when compared to IgG control; #, p<0.05, ##, p<0.01 compared with IgG/HIV-1 group.
###end p 55
###begin p 56
###xml 293 300 293 300 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0005397-g003">Figs. 3</xref>
###xml 305 307 305 307 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0005397-g006">6I</xref>
###xml 726 733 726 733 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0005397-g006">Fig. 6H</xref>
###xml 1091 1101 1084 1094 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0005397-g006">Fig. 6I, J</xref>
###xml 106 111 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 171 176 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 273 278 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 329 334 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 453 458 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 534 539 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 1195 1200 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
To validate type I IFNs were the diffusible factors that regulated TRAIL, we transferred supernatant from HIV-1-infected MDM to uninfected MDM. Exposure of control MDM to HIV-1-infected supernatants for 2 hours led to a dramatic activation of STAT1 similar to that seen in HIV-1-infected MDM (Figs. 3 and 6I). Because binding of HIV-1 virions or gp120 may also activate STAT1, we used centrifugal filters with 100 kDa molecular weight pores to separate HIV-1 virions and gp120 from lower molecular weight compounds. After filtration, HIV-1 RTase activity was completely lost (data not shown), suggesting successful removal of virions. The lower molecular weight fraction after filtration induced strong STAT1 phosphorylation (Fig. 6H), confirming diffusible factors (<100 kDa) are capable of activating STAT1. Interestingly, IFN-alpha-neutralizing antibody reduced STAT1 activation (48% inhibition) and significantly reduced TRAIL expression levels, whereas IFN-beta-neutralizing antibody treatment did not cause a statistically significant decrease in STAT1 activation or TRAIL expression (Fig. 6I, J). These data demonstrate that type I IFNs, likely IFN-alpha, is released by macrophages upon HIV-1 infection resulting in increased TRAIL levels.
###end p 56
###begin title 57
###xml 52 57 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
STAT1 is essential for IRFs and TRAIL expression in HIV-1-infected macrophages
###end title 57
###begin p 58
###xml 210 214 210 214 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005397-Frank1">[50]</xref>
###xml 401 408 397 404 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0005397-g007">Fig. 7A</xref>
###xml 464 471 460 467 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0005397-g007">Fig. 7B</xref>
###xml 481 488 477 484 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0005397-g007">Fig. 7C</xref>
###xml 502 509 498 505 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0005397-g007">Fig. 7D</xref>
###xml 43 48 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 234 239 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 312 317 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 362 367 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 424 429 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 649 654 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
We next determined whether STAT1 modulates HIV-1-induced TRAIL expression in MDM. Fludarabine, a compound that has been shown to specifically inhibit STAT1 activation and induce loss of STAT1 mRNA and proteins [50], was used to block HIV-1-mediated STAT1 activation. When used at 1 microM, fludarabine abolished HIV-1-induced phosphorylation of STAT1 as well as HIV-1-induced increase in total STAT1 (Fig. 7A). Accordingly, HIV-1-induced gene expression of TRAIL (Fig. 7B), IRF-1 (Fig. 7C), and IRF-7 (Fig. 7D) were completely blocked by fludarabine treatment. These results suggest that STAT1 is essential for IRF-1, IRF-7, and TRAIL expression in HIV-1-infected macrophages.
###end p 58
###begin title 59
###xml 19 24 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
Fludarabine blocks HIV-1-induced STAT1 activation and gene expression of IRF-1, IRF-7, and TRAIL in macrophages.
###end title 59
###begin p 60
###xml 353 358 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
A. MDM were treated with fludarabine at 1 microM 3 days after infection. P-STAT1 and total STAT1 were detected by Western blotting at 5 days after infection. beta-actin was used as a loading control. B-D. Real-time RT-PCR was used to detect TRAIL (B), IRF-1 (C), and IRF-7 (D). **, p<0.05 compared with DMSO control. ##; p<0.01 compared to DMSO-treated HIV-1 group.
###end p 60
###begin title 61
Discussion
###end title 61
###begin p 62
###xml 363 369 363 369 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0005397-g001">Fig. 1</xref>
###xml 371 372 371 372 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0005397-g002">2</xref>
###xml 464 470 464 470 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0005397-g003">Fig. 3</xref>
###xml 554 560 554 560 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0005397-g004">Fig. 4</xref>
###xml 647 653 647 653 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0005397-g006">Fig. 6</xref>
###xml 655 656 655 656 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0005397-g007">7</xref>
###xml 779 785 779 785 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0005397-g004">Fig. 4</xref>
###xml 787 788 787 788 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0005397-g006">6</xref>
###xml 790 791 790 791 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0005397-g007">7</xref>
###xml 1122 1128 1122 1128 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0005397-g004">Fig. 4</xref>
###xml 1316 1322 1316 1322 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0005397-g008">Fig. 8</xref>
###xml 47 52 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 220 225 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 305 310 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 375 380 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 1274 1279 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
The molecular mechanisms of TRAIL induction by HIV-1 in macrophages are not completely understood. Here we investigated the regulation of TRAIL as well as the upstream molecular events responsible for TRAIL induction in HIV-1-infected macrophages. We demonstrated that upregulation of TRAIL expression in HIV-1-infected MDM was predominantly membrane-associated (Fig. 1, 2). HIV-1 infection induced IRF-1, IRF-7 gene expression and activated STAT1 in macrophages (Fig. 3). IRF-1 and IRF-7 promoted Type I IFNs production and subsequent STAT1 activation (Fig. 4). Type I IFNs and STAT1 activation further increased IRF-1 and IRF-7 gene expression (Fig. 6, 7). Blocking signaling factors, including IRF-1, IRF-7, type I IFNs, or STAT1, significantly reduced TRAIL gene expression (Fig. 4, 6, 7). These data provide insight to the detailed regulation of TRAIL and identify IRF-1, IRF-7, type I IFNs, and STAT1 as critical signaling intermediates for TRAIL induction. Although IRFs have been reported to regulate type I IFNs, we were surprised to find that IRF-3 is not as critical as IRF-1 or IRF-7 in the signaling cascade (Fig. 4). Instead, a positive feedback loop between intracellular IRF1, IRF-7, STAT1 and soluble type I IFNs exists and cooperatively regulates TRAIL in HIV-1-infected macrophages (see scheme in Fig. 8).
###end p 62
###begin title 63
###xml 73 78 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
A feedback loop among Type I IFNs and IRFs regulates TRAIL Expression in HIV-1-infected macrophages.
###end title 63
###begin p 64
###xml 129 134 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 146 151 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 551 556 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
A positive feedback loop exists among intracellular IRFs gene expression and soluble type I IFNs induction in macrophages during HIV-1 infection. HIV-1 infection induces IRF-1 and IRF-7 gene expression. IRF-1 and IRF-7 promotes type I IFNs activities and activate STAT1. Type I IFNs diffuse and further promote STAT1 activation and IRF-1 and IRF-7 expression in uninfected macrophages. Blocking of either IRF-1, IRF-7, type I IFNs, or STAT1 reduces TRAIL expression. TRAIL has been reported to mediate the apoptosis of CD4+ T cells and participate in HIV-1 pathogenesis.
###end p 64
###begin p 65
###xml 3 7 3 7 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005397-Ryan1">[10]</xref>
###xml 9 13 9 13 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005397-Huang1">[11]</xref>
###xml 33 36 33 36 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005397-Kayagaki1">[6]</xref>
###xml 37 40 37 40 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005397-Herbeuval2">[9]</xref>
###xml 110 115 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 304 309 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 456 461 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 885 890 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 925 930 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
We [10], [11], as well as others [6]-[9] have identified TRAIL-induced apoptosis in several cell types during HIV-1 infection. The exact pathological consequences of the increased membrane-bound TRAIL in macrophages and in other cell types remain to be established. Given that TRAIL preferentially kills HIV-1-infected macrophages, it is plausible that the initial increase in TRAIL is part of the innate immune response directed toward the elimination of HIV-1-infected cells. Other unexpected target of TRAIL, particularly uninfected CD4+ T cells, may add to the complexity of TRAIL-mediated cell death. The increased membrane-bound form of TRAIL in macrophages may team together with either membrane-bound or soluble form of TRAIL in monocytes and CD4+ T cells, possibly causing apoptosis of bystander CD4+ T cells. This adverse effect of TRAIL on the adaptive immune system during HIV-1 infection may help to explain why HIV-1 persists even in the presence of elevated soluble and membrane-bound TRAIL.
###end p 65
###begin p 66
###xml 167 171 167 171 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005397-Lohoff1">[30]</xref>
###xml 172 176 172 176 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005397-Honda1">[32]</xref>
###xml 277 281 277 281 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005397-Tamura1">[51]</xref>
###xml 379 383 379 383 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005397-Sgarbanti1">[52]</xref>
###xml 541 545 541 545 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005397-Herbeuval4">[36]</xref>
###xml 754 760 754 760 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0005397-g003">Fig. 3</xref>
###xml 834 841 834 841 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0005397-g004">Fig. 4F</xref>
###xml 984 991 984 991 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0005397-g004">Fig. 4F</xref>
###xml 1192 1196 1188 1192 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005397-Sgarbanti2">[53]</xref>
###xml 332 337 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 407 412 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 618 623 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 726 731 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 815 820 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 965 970 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 1036 1041 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 1160 1165 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 1246 1251 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 1398 1403 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 1449 1454 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
Members of the IRF family are important antiviral transcription factors. IRF-3 and IRF-7 participate in immune responses and are primarily associated with Type I IFNs [30]-[32]. In addition, IRF-1, IRF-5, and IRF-8 can also contribute to type I IFNs induction (for review, see [51]). Increased IRF-1 expression has been reported in HIV-1-infected Jurkat and primary CD4+ T cells [52]. IRF-7 is increased in HIV-1-infected individuals in plasmacytoid dendritic cells, another mononuclear phagocyte cell type and the major IFN-producing cells [36]. However, limited information on the regulation and function of IRFs in HIV-1-infected macrophages has been reported to date. Our data show increased IRF-1 and IRF-7 expression in HIV-1-infected macrophages (Fig. 3), and that IRF-7 knockdown in macrophages facilitated HIV-1 replication (Fig. 4F), highlighting the importance of IRF-7 in the antiviral response of macrophages. In contrast, knockdown of IRF-1 inhibited HIV-1 replication (Fig. 4F). The difference between IRF-1 and IRF-7 on HIV-1 replication may be due to the requirement of IRF-1, but not IRF-7, for full NF-kappaB transcriptional activity at the HIV-1 long term repeat enhancer [53]. The unique roles of IRF-1 in the enhancement of HIV-1 replication and induction of death ligand TRAIL provide a potentially novel therapeutic target, and inhibition of IRF-1 may simultaneously reduce HIV-1 viral load and alleviate macrophage-mediated HIV-1 pathogenesis.
###end p 66
###begin p 67
###xml 84 88 84 88 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005397-Clarke1">[38]</xref>
###xml 89 93 89 93 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005397-Kirshner1">[40]</xref>
###xml 195 199 195 199 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005397-RomieuMourez1">[41]</xref>
###xml 431 438 431 438 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0005397-g004">Fig. 4G</xref>
###xml 661 668 661 668 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0005397-g004">Fig. 4E</xref>
###xml 787 797 787 797 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0005397-g006">Fig. 6D, E</xref>
###xml 278 283 <span type="species:ncbi:9606">human</span>
###xml 333 338 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 518 523 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 763 768 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 973 978 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 1097 1102 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 1206 1211 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
IRF-1 and IRF-3 have been shown to regulate TRAIL transcription in tumor cell lines [38]-[40]. More recently, overexpression of IRF-7 has been found to enhance TRAIL transcription in macrophages [41]. When we applied siRNA to knockdown IRF-1, IRF-3, or IRF-7 gene expression in human macrophages, the increase of TRAIL expression by HIV-1 infection was reduced by the IRF-1 and the IRF-7 knockdown, but not by the IRF-3 knockdown (Fig. 4G). This is, to the best of our knowledge, the first report of IRFs knockdown in HIV-1-infected macrophages. Knockdown of IRF-1 and IRF-7 reduced STAT1 phosphorylation, an essential component for type I IFNs responsiveness (Fig. 4E). However, type I IFNs-neutralizing antibodies did not completely block TRAIL upregulation in HIV-1-infected culture (Fig. 6D, E), suggesting the involvement of a type I IFNs-independent pathway in the induction of TRAIL. These type I IFNs-dependent and -independent mechanisms may work concomitantly in HIV-1-infected culture to induce TRAIL expression. Our analysis also found that IRF-5 gene expression could be induced upon HIV-1 infection in macrophages but in lower abundance. In addition, IRF-8 gene expression was not induced by HIV-1 infection but was expressed at a higher amount. The role of these additional members of IRFs in the type I IFNs production and TRAIL regulation remains to be elucidated.
###end p 67
###begin p 68
###xml 374 378 374 378 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005397-Takeuchi1">[54]</xref>
###xml 533 537 533 537 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005397-Brown1">[55]</xref>
###xml 810 817 810 817 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="pone.0005397.s002">Fig. S2</xref>
###xml 906 910 906 910 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005397-Kato1">[56]</xref>
###xml 911 915 911 915 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005397-Yoneyama2">[58]</xref>
###xml 1051 1055 1051 1055 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005397-Yoneyama1">[57]</xref>
###xml 1057 1061 1057 1061 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005397-Kato2">[59]</xref>
###xml 527 532 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 615 620 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 699 704 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 1184 1189 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 1230 1235 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
The upstream molecular mechanisms resulting in the activation of IRF-1 and IRF-7 during viral infection have begun to be elucidated in recent years. Toll-like receptors (TLRs) and RIG-I-like receptors are two separate classes of pattern-recognition receptors (PRRs) that detect viral infection and initiate signaling cascades including IRFs and type I IFNs (for review, see [54]). However, TLR signaling cascade, which can be activated in plasmacytoid dendritic cells, fails to promote activation in macrophages in response to HIV-1 [55]. We suspect that other viral sensing pathways may lead to IRFs activation in HIV-1-infected macrophages. We tested RIG-I, a TLR-independent PRRs, and found that HIV-1 infection increased RIG-I protein levels, and the increase occurred as early as one day after infection (Fig. S2). Activation of RIG-I leads to a signaling results in the activation of IRF-3 and IRF-7 [56]-[58]. Furthermore, melanoma differentiation-associated gene 5, another RIG-I like receptor, has been reported to activate IRF-1, -3, and -7 [57], [59]. Despite our extensive studies, we cannot exclude the potential roles of TLRs in the regulation of IRF-1 and IRF-7 during HIV-1 infection. The upregulation of RIG-I by HIV-1 infection in macrophages is novel and interesting, however its relationship with IRF-1 and IRF-7 regulation remains the subject of further investigation.
###end p 68
###begin p 69
###xml 132 136 132 136 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005397-Okumura1">[60]</xref>
###xml 525 533 525 533 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="pone.0005397.s001">Fig. S1A</xref>
###xml 676 680 676 680 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005397-Brown1">[55]</xref>
###xml 934 938 934 938 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005397-Negishi1">[61]</xref>
###xml 9 14 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 175 180 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 404 409 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 508 513 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 649 654 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 788 793 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
Recently HIV-1 accessory proteins, VPR and Vif, have been reported to degrade IRF-3 through ubiquitin-associated proteosome pathway [60]. If IRF-3 degradation occurred in our HIV-1-infected MDM culture, it could skew the interpretations of our current results. To discount this, we have tested the IRF-3 protein levels by Western blotting and found no dramatic degradation of IRF-3 in our MDM during the HIV-1 infection course (data not shown). In fact, there is a transient increase of IRF-3 at 5 days post HIV-1 infection (Fig. S1A). This is more comparable with a previous publication, which showed neither degradation nor activation of IRF-3 in HIV-1-infected macrophages [55]. This inconsistency in the literature may be explained by the differences in cellular models and stages of HIV-1 infection. In addition, a cell type-specific role for IRF-1 to supplant the requirement for IRF-3 in macrophages has been reported recently [61]. Whether upregulation of IRF-1 and IRF-7 could potentially restore the function of IRF-3 awaits future investigation.
###end p 69
###begin p 70
###xml 245 249 245 249 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005397-Gessani1">[23]</xref>
###xml 251 255 251 255 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005397-Siegal1">[24]</xref>
###xml 257 261 257 261 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005397-Szebeni1">[62]</xref>
###xml 458 462 458 462 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005397-Fischl1">[63]</xref>
###xml 114 119 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 330 335 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 755 760 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
Our results identify type I IFNs as a critical component of the signaling cascade regulating TRAIL expression. In HIV-1 infection, type I IFNs are produced mainly by plasmacytoid dendritic cells and in lower amounts by monocytes and macrophages [23], [24], [62]. Interestingly, type I IFNs have been tested in clinical trials for HIV-1 treatment and resulted in a transiently decreased viral load and increased hematologic toxicity and peripheral neuropathy [63]. Although type I IFNs activate macrophages and improve the immune function of macrophages, our data found endogenous type I IFNs do not significantly decrease viral replication in infected MDM cultures (data not shown). This contradiction suggests that there is a complex interaction between HIV-1 and macrophages, where the innate immune response may contribute to viral replication.
###end p 70
###begin p 71
###xml 133 137 133 137 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005397-Bovolenta1">[64]</xref>
###xml 139 143 139 143 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005397-Federico1">[65]</xref>
###xml 285 289 285 289 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005397-Durbin1">[48]</xref>
###xml 291 295 291 295 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005397-Meraz1">[49]</xref>
###xml 429 433 429 433 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005397-Darnell1">[26]</xref>
###xml 435 439 435 439 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005397-Wen1">[66]</xref>
###xml 553 559 553 559 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0005397-g003">Fig. 3</xref>
###xml 659 665 659 665 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0005397-g007">Fig. 7</xref>
###xml 896 900 896 900 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005397-Li1">[67]</xref>
###xml 901 905 901 905 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005397-Sato3">[69]</xref>
###xml 1379 1382 1379 1382 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005397-Zhang1">[7]</xref>
###xml 1384 1387 1384 1387 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005397-Yang1">[8]</xref>
###xml 1389 1393 1389 1393 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005397-Federico1">[65]</xref>
###xml 1395 1399 1395 1399 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005397-Ihle1">[70]</xref>
###xml 1400 1404 1400 1404 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005397-Heinrich1">[72]</xref>
###xml 20 25 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 116 119 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 467 472 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 1211 1216 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 1291 1296 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 1551 1556 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
STAT1 activation in HIV-1-infected MDM and peripheral blood mononuclear cells has been reported and correlated with HIV pathogenesis [64], [65]. STAT1 activation seems to primarily be involved in the response to type I and II IFNs and involves phosphorylation of Tyr 701 and/or Ser727 [48], [49]. Tyr701 is obligatory for STAT1 activation, while Ser727 may be required for the maximal induction of STAT1-mediated gene activation [26], [66]. We have demonstrated that HIV-1 infection increased STAT1 phosphorylation at Tyr701 and total STAT1 expression (Fig. 3) and that the activation of STAT1 is essential for IRF-1 and IRF-7 expression and TRAIL induction (Fig. 7). The potential mechanism(s) linking upstream STAT1 activation to IRF-1 and IRF-7 is not investigated in the current study. The activation of STAT1 could directly bind to the IRF-1 or IRF-7 promoter and turn on gene transcription [67]-[69]. Moreover, a reciprocal build up between IRF and IFN in the later stages of infection may contribute to the changes of gene expression and STAT1 activation. In addition, it should be noted that other cytokines such as epidermal growth factor, platelet-derived growth factor, and interleukin-6, along with HIV-1 virions and viral proteins such as gp120, Tat, and Nef may be secreted by HIV-1-infected macrophages thereby mediating type I IFNs production or STAT1 activation [7], [8], [65], [70]-[72]. Nevertheless, our data strongly support a critical role for IRF-1, IRF-7, and type I IFNs in the induction of macrophage STAT1 activation during HIV-1 infection.
###end p 71
###begin p 72
###xml 82 85 82 85 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005397-Ehrlich1">[4]</xref>
###xml 87 91 87 91 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005397-Sato1">[28]</xref>
###xml 93 97 93 97 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005397-Tecchio1">[73]</xref>
###xml 311 317 304 310 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0005397-g005">Fig. 5</xref>
###xml 448 454 441 447 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0005397-g001">Fig. 1</xref>
###xml 565 568 558 561 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005397-Herbeuval1">[5]</xref>
###xml 199 204 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 420 425 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 559 564 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
Biologically active forms of TRAIL include membrane-bound TRAIL and soluble TRAIL [4], [28], [73]. In our study, both transcription and membrane-bound levels of TRAIL were significantly increased in HIV-1-infected or IFN-treated MDM but not by inflammatory cytokines TNF-alpha- or IL-1beta-mediated activation (Fig. 5). Notably, soluble TRAIL was secreted by macrophages following type I interferon treatment but not by HIV-1-infected macrophages (Fig. 1). This is consistent with a previous report that there was no soluble TRAIL production upon exposure to HIV-1 [5]. The low production of soluble TRAIL despite the dramatic increase of transcription and membrane-bound TRAIL is probably cell type-specific and the regulation mechanisms warrants future investigation.
###end p 72
###begin p 73
###xml 89 94 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 200 205 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 293 298 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 462 467 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
In summary, our current study revealed the signaling mechanisms of TRAIL upregulation in HIV-1-infected macrophages. The role of IRF-1, IRF-7, type I IFNs, and STAT1 in the regulation of TRAIL during HIV-1 infection of macrophages is important and adds to our understanding of pathogenesis of HIV-1. Identifying cytotoxicity in the antiviral response to type I IFNs and its signaling mechanism would potentially provide targets for therapeutic interventions for HIV-1 infection.
###end p 73
###begin title 74
Supporting Information
###end title 74
###begin p 75
###xml 52 57 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 95 100 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 586 589 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
siRNA knockdown of IRF-3 reduces CCL5 production in HIV-1-infected macrophages. Two days after HIV-1 infection, MDM were transfected with siRNA for IRF-3. A. Ninety-six hours after transfection, IRF-3 was detected by Western blotting. beta-actin was used as a loading control. Levels of IRF-3 were normalized as a ratio of IRF-3 to beta-actin after densimetrical quantification and shown as fold change relative to non-specific siRNA control. B. CCL5 levels were determined by ELISA. ** indicates p<0.01 when compared to non-specific siRNA control; ## indicates p<0.01 when compared to HIV group with siRNA control. Data are representative of three donors.
###end p 75
###begin p 76
(0.85 MB TIF)
###end p 76
###begin p 77
Click here for additional data file.
###end p 77
###begin p 78
###xml 15 20 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 89 94 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
Infection with HIV-1 induces an increase of RIG-I in macrophages. MDM were infected with HIV-1 and cell lysates were collected 1, 3, 5, and 7 days after infection. RIG-I was detected by Western blotting and beta-actin was used as a loading control. Levels of RIG-I were normalized as a ratio of RIG-I to beta-actin after densimetrical quantification and shown as fold change relative to control (1 dpi). Results are shown as the average+/-SEM in experiments performed with five different donors. *, p<0.05 compared with day-matched control. **, p<0.01 compared to day-matched control.
###end p 78
###begin p 79
(0.72 MB TIF)
###end p 79
###begin p 80
Click here for additional data file.
###end p 80
###begin p 81
We kindly acknowledge Dr. Dongsheng Xu, Dr. Yanjun Jiang, Dr. You Zhou, Dr. Hui Peng, and Matthew Beaver who provided technical support for this work. Dr. Runqing Lu, Dr. Nathan Erdmann, and Tess Eidem provided valuable comments and suggestions about the manuscript. Ms. Julie Ditter, Johna Belling, Robin Taylor, Myhanh Che, Na Ly, and Emilie Scoggins provided outstanding administrative support.
###end p 81
###begin title 82
References
###end title 82
###begin article-title 83
Identification and characterization of a new member of the TNF family that induces apoptosis.
###end article-title 83
###begin article-title 84
TRAIL-R as a negative regulator of innate immune cell responses.
###end article-title 84
###begin article-title 85
CD4+ T-cell help controls CD8+ T-cell memory via TRAIL-mediated activation-induced cell death.
###end article-title 85
###begin article-title 86
###xml 49 54 <span type="species:ncbi:9606">human</span>
Regulation of soluble and surface-bound TRAIL in human T cells, B cells, and monocytes.
###end article-title 86
###begin article-title 87
###xml 49 54 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 64 72 <span type="species:ncbi:9606">patients</span>
TNF-related apoptosis-inducing ligand (TRAIL) in HIV-1-infected patients and its in vitro production by antigen-presenting cells.
###end article-title 87
###begin article-title 88
###xml 56 61 <span type="species:ncbi:9606">human</span>
Involvement of TNF-related apoptosis-inducing ligand in human CD4+ T cell-mediated cytotoxicity.
###end article-title 88
###begin article-title 89
###xml 30 33 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 126 131 <span type="species:ncbi:9606">human</span>
###xml 147 152 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
Identification of a potential HIV-induced source of bystander-mediated apoptosis in T cells: upregulation of trail in primary human macrophages by HIV-1 tat.
###end article-title 89
###begin article-title 90
###xml 23 51 <span type="species:ncbi:12721">human immunodeficiency virus</span>
Monocytes treated with human immunodeficiency virus Tat kill uninfected CD4(+) cells by a tumor necrosis factor-related apoptosis-induced ligand-mediated mechanism.
###end article-title 90
###begin article-title 91
###xml 58 63 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
CD4+ T-cell death induced by infectious and noninfectious HIV-1: role of type 1 interferon-dependent, TRAIL/DR5-mediated apoptosis.
###end article-title 91
###begin article-title 92
###xml 47 52 <span type="species:ncbi:9606">Human</span>
###xml 82 87 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
TNF-Related Apoptosis-Inducing Ligand Mediates Human Neuronal Apoptosis: Links to HIV-1 Associated Dementia.
###end article-title 92
###begin article-title 93
###xml 28 33 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
TRAIL-mediated apoptosis in HIV-1-infected macrophages is dependent on the inhibition of Akt-1 phosphorylation.
###end article-title 93
###begin article-title 94
Apo2L/TRAIL: apoptosis signaling, biology, and potential for cancer therapy.
###end article-title 94
###begin article-title 95
###xml 51 56 <span type="species:ncbi:9606">human</span>
Cellular IAP1 regulates TRAIL-induced apoptosis in human fetal cortical neural progenitor cells.
###end article-title 95
###begin article-title 96
###xml 22 27 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
Macrophage tropism of HIV-1.
###end article-title 96
###begin article-title 97
###xml 54 59 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
The macrophage in the persistence and pathogenesis of HIV-1 infection.
###end article-title 97
###begin article-title 98
###xml 68 76 <span type="species:ncbi:9606">patients</span>
Immunohistochemical identification of HTLV-III antigen in brains of patients with AIDS.
###end article-title 98
###begin article-title 99
The role of mononuclear phagocytes in HTLV-III LAV infection.
###end article-title 99
###begin article-title 100
###xml 13 23 <span type="species:ncbi:11676">AIDS virus</span>
###xml 65 73 <span type="species:ncbi:9606">patients</span>
Detection of AIDS virus in macrophages in brain tissue from AIDS patients with encephalopathy.
###end article-title 100
###begin article-title 101
###xml 34 39 <span type="species:ncbi:9606">Human</span>
Chemokine Receptor Utilization by Human Immundeficiency Virus Type 1 Isolates That Replicate in Microglia.
###end article-title 101
###begin article-title 102
Monocyte-mediated tumoricidal activity via the tumor necrosis factor- related cytokine, TRAIL.
###end article-title 102
###begin article-title 103
###xml 55 60 <span type="species:ncbi:9606">human</span>
Genomic organization and transcriptional regulation of human Apo2/TRAIL gene.
###end article-title 103
###begin article-title 104
###xml 79 84 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
Regulation of TNF-related apoptosis-inducing ligand on primary CD4+ T cells by HIV-1: role of type I IFN-producing plasmacytoid dendritic cells.
###end article-title 104
###begin article-title 105
###xml 32 67 <span type="species:ncbi:11676">human immunodeficiency virus type 1</span>
###xml 93 98 <span type="species:ncbi:9606">human</span>
Induction of beta interferon by human immunodeficiency virus type 1 and its gp120 protein in human monocytes-macrophages: role of beta interferon in restriction of virus replication.
###end article-title 105
###begin article-title 106
###xml 65 70 <span type="species:ncbi:9606">human</span>
The nature of the principal type 1 interferon-producing cells in human blood.
###end article-title 106
###begin article-title 107
Type I interferons and limitin: a comparison of structures, receptors, and functions.
###end article-title 107
###begin article-title 108
Jak-STAT pathways and transcriptional activation in response to IFNs and other extracellular signaling proteins.
###end article-title 108
###begin article-title 109
Stats: transcriptional control and biological impact.
###end article-title 109
###begin article-title 110
Antiviral responses by natural killer cells through TRAIL induction by interferon-alpha/beta.
###end article-title 110
###begin article-title 111
Subunit of an alpha-interferon-responsive transcription factor is related to interferon regulatory factor and Myb families of DNA-binding proteins.
###end article-title 111
###begin article-title 112
Interferon regulatory factor-1 is required for a T helper 1 immune response in vivo.
###end article-title 112
###begin article-title 113
Distinct and essential roles of transcription factors IRF-3 and IRF-7 in response to viruses for IFN-alpha/beta gene induction.
###end article-title 113
###begin article-title 114
IRF-7 is the master regulator of type-I interferon-dependent immune responses.
###end article-title 114
###begin article-title 115
Regulated expression of a gene encoding a nuclear factor, IRF-1, that specifically binds to IFN-beta gene regulatory elements.
###end article-title 115
###begin article-title 116
###xml 96 101 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
Activation of signal transduction and apoptosis in healthy lymphomonocytes exposed to bystander HIV-1-infected cells.
###end article-title 116
###begin article-title 117
###xml 18 23 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
IRF regulation of HIV-1 long terminal repeat activity.
###end article-title 117
###begin article-title 118
###xml 105 110 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 120 128 <span type="species:ncbi:9606">patients</span>
Differential expression of IFN-alpha and TRAIL/DR5 in lymphoid tissue of progressor versus nonprogressor HIV-1-infected patients.
###end article-title 118
###begin article-title 119
IRFs: master regulators of signalling by Toll-like receptors and cytosolic pattern-recognition receptors.
###end article-title 119
###begin article-title 120
Tumor suppressor IRF-1 mediates retinoid and interferon anticancer signaling to death ligand TRAIL.
###end article-title 120
###begin article-title 121
IFN-gamma enhances TRAIL-induced apoptosis through IRF-1.
###end article-title 121
###begin article-title 122
Identification of TRAIL as an interferon regulatory factor 3 transcriptional target.
###end article-title 122
###begin article-title 123
###xml 104 109 <span type="species:ncbi:9606">human</span>
Distinct roles for IFN regulatory factor (IRF)-3 and IRF-7 in the activation of antitumor properties of human macrophages.
###end article-title 123
###begin article-title 124
###xml 39 67 <span type="species:ncbi:12721">human immunodeficiency virus</span>
Efficient isolation and propagation of human immunodeficiency virus on recombinant colony-stimulating factor 1-treated monocytes.
###end article-title 124
###begin article-title 125
###xml 14 19 <span type="species:ncbi:9606">Human</span>
Regulation of Human Immunodeficiency Virus Type 1 Infection, beta- Chemokine Production, and CCR5 Expression in CD40L-Stimulated Macrophages: Immune Control of Viral Entry.
###end article-title 125
###begin article-title 126
Essential role of interferon regulatory factor 3 in direct activation of RANTES chemokine transcription.
###end article-title 126
###begin article-title 127
###xml 74 79 <span type="species:ncbi:9606">human</span>
###xml 113 141 <span type="species:ncbi:12721">human immunodeficiency virus</span>
Differential regulation of proinflammatory and hematopoietic cytokines in human macrophages after infection with human immunodeficiency virus.
###end article-title 127
###begin article-title 128
###xml 78 83 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
Expression of inducible nitric oxide synthase, interleukin-1 and caspase-1 in HIV-1 encephalitis.
###end article-title 128
###begin article-title 129
###xml 62 67 <span type="species:ncbi:9606">human</span>
Lipopolysaccharide induces expression of APO2 ligand/TRAIL in human monocytes and macrophages.
###end article-title 129
###begin article-title 130
###xml 27 32 <span type="species:ncbi:10090">mouse</span>
Targeted disruption of the mouse Stat1 gene results in compromised innate immunity to viral disease.
###end article-title 130
###begin article-title 131
###xml 41 45 <span type="species:ncbi:10090">mice</span>
Targeted disruption of the Stat1 gene in mice reveals unexpected physiologic specificity in the JAK-STAT signaling pathway.
###end article-title 131
###begin article-title 132
Fludarabine-induced immunosuppression is associated with inhibition of STAT1 signaling.
###end article-title 132
###begin article-title 133
The IRF family transcription factors in immunity and oncogenesis.
###end article-title 133
###begin article-title 134
###xml 14 44 <span type="species:ncbi:11676">human immunodeficiency virus 1</span>
Modulation of human immunodeficiency virus 1 replication by interferon regulatory factors.
###end article-title 134
###begin article-title 135
###xml 71 76 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
IRF-1 Is Required for Full NF-{kappa}B Transcriptional Activity at the HIV-1 LTR Enhancer.
###end article-title 135
###begin article-title 136
Innate immunity to virus infection.
###end article-title 136
###begin article-title 137
###xml 0 5 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
HIV-1 activates macrophages independent of Toll-like receptors.
###end article-title 137
###begin article-title 138
Cell type-specific involvement of RIG-I in antiviral response.
###end article-title 138
###begin article-title 139
Shared and unique functions of the DExD/H-box helicases RIG-I, MDA5, and LGP2 in antiviral innate immunity.
###end article-title 139
###begin article-title 140
The RNA helicase RIG-I has an essential function in double-stranded RNA-induced innate antiviral responses.
###end article-title 140
###begin article-title 141
Differential roles of MDA5 and RIG-I helicases in the recognition of RNA viruses.
###end article-title 141
###begin article-title 142
###xml 0 5 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
HIV-1 accessory proteins VPR and Vif modulate antiviral response by targeting IRF-3 for degradation.
###end article-title 142
###begin article-title 143
Evidence for licensing of IFN-gamma-induced IFN regulatory factor 1 transcription factor by MyD88 in Toll-like receptor-dependent gene induction program.
###end article-title 143
###begin article-title 144
###xml 33 68 <span type="species:ncbi:11676">human immunodeficiency virus type 1</span>
###xml 72 77 <span type="species:ncbi:9606">human</span>
Induction of alpha interferon by human immunodeficiency virus type 1 in human monocyte-macrophage cultures.
###end article-title 144
###begin article-title 145
###xml 122 130 <span type="species:ncbi:9606">patients</span>
###xml 136 139 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
Safety and antiviral activity of combination therapy with zidovudine, zalcitabine, and two doses of interferon-alpha2a in patients with HIV. AIDS Clinical Trials Group Study 197.
###end article-title 145
###begin article-title 146
###xml 46 74 <span type="species:ncbi:12721">human immunodeficiency virus</span>
Constitutive activation of STATs upon in vivo human immunodeficiency virus infection.
###end article-title 146
###begin article-title 147
###xml 0 5 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 29 34 <span type="species:ncbi:9606">human</span>
HIV-1 Nef activates STAT1 in human monocytes/macrophages through the release of soluble factors.
###end article-title 147
###begin article-title 148
Maximal activation of transcription by Stat1 and Stat3 requires both tyrosine and serine phosphorylation.
###end article-title 148
###begin article-title 149
Formation of STAT1-STAT2 heterodimers and their role in the activation of IRF-1 gene transcription by interferon-alpha.
###end article-title 149
###begin article-title 150
Differential viral induction of distinct interferon-alpha genes by positive feedback through interferon regulatory factor-7.
###end article-title 150
###begin article-title 151
Positive feedback regulation of type I IFN genes by the IFN-inducible transcription factor IRF-7.
###end article-title 151
###begin article-title 152
Signaling through the hematopoietic cytokine receptors.
###end article-title 152
###begin article-title 153
Regulation of STAT-dependent pathways by growth factors and cytokines.
###end article-title 153
###begin article-title 154
Interleukin-6-type cytokine signalling through the gp130/Jak/STAT pathway.
###end article-title 154
###begin article-title 155
IFN{alpha}-stimulated neutrophils and monocytes release a soluble form of TNF-related apoptosis-inducing ligand (TRAIL/Apo-2 ligand) displaying apoptotic activity on leukemic cells.
###end article-title 155
###begin p 156
###xml 0 21 0 21 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Competing Interests: </bold>
Competing Interests: The authors have declared that no competing interests exist.
###end p 156
###begin p 157
###xml 0 9 0 9 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Funding: </bold>
Funding: This work was supported in part by research grants by the National Institutes of Health: R01 NS41858, R01NS61642, R21MH83525, P20RR15635 and P01NS43985 to JZ. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
###end p 157

